...at TCR2 Therapeutics Inc. (NASDAQ:TCRR) in 2017-19 and before that co-founded and served as CSO at Cour Pharmaceutical...

...therapy that induces tolerance. On Tuesday at the United European Gastroenterology Week meeting in Barcelona, Cour Pharmaceutical Development Co. Inc....

...two other companies have platforms to deliver autoantigens to the liver: Topas Therapeutics GmbH and Cour Pharmaceutical Development Co. Inc....

...cells, the engineered protein antigens will be recognized as self along with the erythrocyte components. Cour Pharmaceutical Development Co. Inc....
...AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Anokion S.A., Ecublens, Switzerland Brigham and Women's Hospital, Boston, Mass. Cour Pharmaceutical Development Co. Inc....

...discovery or preclinical deals for GI diseases since, including deals in December and January with Cour Pharmaceutical Development Co. Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Cour Pharmaceutical Development Co. Inc....

...multiple allergens. The partners also market the mAb for urticaria. Nadeau is also working with Cour Pharmaceutical Development Co. Inc....

...the space of a month. Takeda's GI Drug Discovery Unit (DDU) announced a deal with Cour Pharmaceutical Development Co. Inc....

...which Takeda exercises its option. The companies declined to provide further financial terms or details. Cour Pharmaceutical Development Co. Inc....

...sites of inflammation and disease symptoms compared with neutral nanoparticles or vehicle. Ongoing studies at Cour Pharmaceutical Development Co. Inc....
...doi:10.1038/scibx.2014.148 Published online Feb. 6, 2014 Patented by Getts Consulting and Project Management; licensed to Cour Pharmaceutical...